Ticker Details
KalVista Pharmaceuticals, Inc. KalVista Pharmaceuticals Inc is a pharmaceuticals company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases.
IPO Date:	April 9, 2015
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$800.15M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.39 | 2.95%
Avg Daily Range (30 D):	$0.42 | 2.67%
Avg Daily Range (90 D):	$0.40 | 2.75%

Institutional Daily Volume
Avg Daily Volume:	.28M
Avg Daily Volume (30 D):	.86M
Avg Daily Volume (90 D):	1.03M

Trade Size
Avg Trade Size (Sh.):	80
Avg Trade Size (Sh.) (30 D):	79
Avg Trade Size (Sh.) (90 D):	79

Institutional Trades
Total Institutional Trades:	1,076
Avg Institutional Trade:	$1.48M
Avg Institutional Trade (30 D):	$1.51M
Avg Institutional Trade (90 D):	$1.53M
Avg Institutional Trade Volume:	.1M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.49M
Avg Closing Trade (30 D):	$1.41M
Avg Closing Trade (90 D):	$1.57M
Avg Closing Volume:	102.31K

News

Jan 9, 2026 @ 1:54 PM Stock Market Today: Dow, Nasdaq 100 And S&P 500 Fu... Source: Rishabh Mishra

Sep 11, 2025 @ 8:25 PM KalVista Posts 154% Expense Jump in Q1 Source: Motley Fool Markets Team

Aug 21, 2025 @ 6:24 PM Ionis Pharma Wins FDA Nod For First RNA-Targeted T... Source: Vandana Singh

May 6, 2025 @ 5:00 PM Angioedema Clinical Trial Pipeline Analysis Demons... Source: Delveinsight

Feb 14, 2024 @ 12:49 PM Citigroup To Rally Over 19%? Here Are 10 Top Analy... Source: Avi Kapoor

Financials
	TTM	Q3 2025	Q1 2026
Basic EPS		$-.92	$-1.12
Diluted EPS		$-.92	$-1.12
Revenue		$13.7M	$1.4M
Gross Profit		$12.47M
Net Income / Loss		$-49.48M	$-60.1M
Operating Income / Loss		$-46.05M	$-59.01M
Cost of Revenue		$1.23M
Net Cash Flow			$-10.03M
PE Ratio

Splits
Nov 22, 2016	1:14